Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Brainstorm Cell Therapeutics Presentations At Neuromuscular Drug Development Summit is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ ... Forward-Looking Statements This press release contains "forward-looking statements" that are ... Read More
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
The impact on biomarkers suggests debamestrocel targets inflammation and neurodegeneration," said Chaim Lebovits, President and CEO of BrainStorm Cell Therapeutics. "We are grateful to the trial ... Read More
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
A conference call and webcast will be held Tomorrow, April 9, at 8:00 a.m. Eastern Time NEW YORK, April 8, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading ... Read More
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
NEW YORK, April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics ... press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including ... Read More
BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. Read More
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm ... stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug ... Read More
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
NurOwn treatment resulted in a positive impact on important CSF biomarkers relevant to ALS compared to placebo. Significant changes in multiple ALS disease pathways support NurOwn's mechanism of ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus